Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 439-441

  Keir, Stephen T ^a   Morton, Christopher L ^b   Billups, Catherine ^b   Smith, Malcolm A ^c   Houghton, Peter J ^b   Gururangan, Sridharan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Preclinical testing; VNP40101M

Indexed keywords

CLORETAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DRUG EVALUATION, PRECLINICAL; FEMALE; GLIOBLASTOMA; GLIOMA; HYDRAZINES; MICE; MICE, INBRED STRAINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 48249095500     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21620     Document Type: Article

References (16)

1. Dropcho EJ. Novel chemotherapeutic approaches to brain tumors. Hematol Oncol Clin North Am 2001;15:1027-1052.
2. Finch RA, Shyam K, Penketh PG, et al. 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-(methylamino)carbonylhydrazine (101 M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 2001;61:3033-3038.
3. Baumann RP, Shyam K, Penketh PG, et al. 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-[(methylamino)carbonyl]hydrazi ne (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 2004;53:288-295.
4. Badruddoja MA, Penne K, Desjardins A, et al. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol 2007;9:70-74.
5. Giles F, Thomas D, Garcia-Manero G, et al. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 2004;10:2908-2917.
6. Giles F, Verstovsek S, Faderl S, et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006;30:1591-1595.
7. Giles F, Verstovsek S, Thomas D, et al. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 2005;11:7817-7824.
8. Murren J, Modiano M, Kummar S, et al. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 2005;23:123-135.
9. Gururangan S, Turner C, Stewart CF, et al. Phase I trial of VNP40101M in children with recurrent brain tumors - A Pediatric Brain Tumor Consortium (PBTC) study. Proc Am Soc Clin Oncol 2007;25:89 (asbtr #2059).
10. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
11. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
12. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
13. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007;6:1620-1628.
14. Badruddoja MA, Keir ST, King I, et al. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol 2007;9:240-244.
15. Chen ZP, Malapetsa A, McQuillan A, et al. Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol Pharmacol 1997;52:815-820.
16. Chen H, Shao C, Shi H, et al. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-a-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol 2007;82:257-262.